The field of immunotherapy represents a market of 100 billion US dollars and is growing steadily. This technology has the possibility to effectively treat lymphoma cancer patients who have stopped responding to Rituximab and/or Yescarta and Kymriah. Inven2 is seeking to license out the technology to pharmaceutical companies and/or biotechnology companies, for clinical trials as second line intervention in Non-Hodgkin Lymphoma patients.
The present invention involves a CAR T cell therapy developed from our original antibodies. The antibodies have been widely tested and found to bind with CD37, which is expressed on malignant B cells. The malignant B cells that down-regulate CD19 and/or CD20, which are the established targets for Non-Hodgkin Lymphoma, may still be sensitive to treatment targeting CD37. Targeting of this protein in the B cells is expected to have a significant beneficial effect on the lymphoma cancer cells in these patients, when other treatments no longer work.
Our data demonstrates an effective and highly significant disease control when the drug is injected by systemic i.p. administration into a preclinical mouse model of lymphoma inoculated with U2932 cells.
WO2017118745 is owned by Oslo University Hospital and it entered national phase in USA (pending), Europe (intention to grant) and Canada (pending).